Iron Dextran Complex
Medically reviewed by Drugs.com. Last updated on May 11, 2019.
(EYE ern DEKS tran KOM pleks)
- Iron Dextran
- Low-Molecular-Weight Iron Dextran (INFeD)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Infed: 50 mg/mL (2 mL)
Brand Names: U.S.
- Iron Salt
The released iron, from the plasma, eventually replenishes the depleted iron stores in the bone marrow where it is incorporated into hemoglobin
IM: 60% absorbed after 3 days; 90% after 1 to 3 weeks, the balance is slowly absorbed over months
IV: Uptake of iron by the reticuloendothelial system appears to be constant at about 10 to 20 mg/hour
Urine and feces via reticuloendothelial system
Onset of Action
Hematologic response to either oral or parenteral iron salts is essentially the same; red blood cell form and color changes within 3 to 10 days
Maximum effect: Peak reticulocytosis occurs in 5 to 10 days, and hemoglobin values increase within 2 to 4 weeks; serum ferritin peak: 7 to 9 days after IV dose
Use: Labeled Indications
Iron deficiency: Treatment of iron deficiency in patients in whom oral administration is unsatisfactory or infeasible
Hypersensitivity to iron dextran or any component of the formulation; any anemia not associated with iron deficiency
Note: A 25 mg test dose should be administered prior to starting iron dextran therapy; observe for at least 1 hour (after test dose) prior to administering the therapeutic dose. Discontinue oral iron products prior to administering iron dextran.
Iron-deficiency anemia: IM (INFeD, DexIron [Canadian product]), IV (INFeD, DexIron [Canadian product]):
Total dose (mL) = 0.0442 (desired hemoglobin - observed hemoglobin) x LBW + (0.26 x LBW)
Desired hemoglobin: Usually 14.8 g/dL
LBW = Lean body weight in kg
Iron replacement therapy for blood loss: IM (INFeD, DexIron [Canadian product]), IV (INFeD, DexIron [Canadian product]): Replacement iron (mg) = blood loss (mL) x Hct
Maximum daily dosage (manufacturer's labeling): Replacement of larger estimated iron deficits (total dose) may be achieved by serial administration of smaller incremental daily doses. Daily dosages should usually be limited to 100 mg iron (2 mL).
Cancer-/chemotherapy-associated anemia: IV: Note: Use the iron-deficiency anemia equation for determining a calculated dose, when applicable.
Weekly administration (off-label dosing; INFeD [Auerbach 2004]):
Weeks 1 to 3: Test dose of 25 mg (over 1 to 2 minutes), followed by 75 mg (bolus) once weekly
Weeks 4 and after: 100 mg over 5 minutes once weekly until the calculated dose is reached
Total dose infusion (off-label dosing; INFeD): Test dose of 25 mg (over 1 to 2 minutes), followed 1 hour later by the balance of the calculated total dose mixed in 500 mL NS and infused at 175 mL/hour (Auerbach 2004)
Refer to adult dosing.
Note: Dexferrum has been discontinued in the US for more than 1 year.
Multiple forms for parenteral iron exist; close attention must be paid to the specific product when ordering and administering; incorrect selection or substitution of one salt form for another (dextran vs sucrose) without proper dosage adjustment may result in serious over- or underdosing; test doses are recommended before starting therapy. Iron dextran: 1 mL provides 50 mg elemental iron. Note: Dosing presented as both mg and mL; use caution when ordering and dispensing.
Iron deficiency anemia: Infants ≥4 months, Children, and Adolescents: IM (INFeD), IV (Dexferrum, INFeD):
Test dose: Usual reported range: 10 to 25 mg (0.2 to 0.5 mL) administered 1 hour prior to starting iron dextran therapy (de la Cruz 2004; Hastings 2012; Reed 1981; Warady 2004; Warady 2014). The manufacturer suggests a fixed test dose of 25 mg (0.5 mL) however, lower doses and a weight-based approach may be preferable and some centers have used:
Infants <10 kg: 10 mg (0.2 mL)
Children 10 to 20 kg: 15 mg (0.3 mL)
Children >20 kg and Adolescents: 25 mg (0.5 mL)
Total replacement dosage of iron dextran for iron deficiency anemia: Calculate total volume of dose (iron dextran 50 mg/mL elemental iron); if total replacement dose is large, may consider dividing total dose and utilizing smaller incremental dosages not to exceed recommended maximum daily dosages for route.
Dose (mL) = 0.0442 (Hbn - Hbo) x LBW + (0.26 x LBW)
LBW = lean body weight in kg. Note: For patients weighing 5 to 15 kg, use actual body weight.
Hbn = desired hemoglobin (g/dL) = 12 g/dL if ≤15 kg or 14.8 g/dL if >15 kg
Hbo = measured hemoglobin (g/dL)
Maximum daily dosage:
IV (Dexferrum, INFeD): 100 mg (2 mL)
Infants <5 kg: 25 mg (0.5 mL)
Children 5 to 10 kg: 50 mg (1 mL)
Children >10 kg and Adolescents: 100 mg (2 mL)
Acute blood loss; total iron replacement dosage: Infants ≥4 months, Children, and Adolescents: IM (INFeD), IV (Dexferrum, INFeD): Note: Assumption: 1 mL of normocytic, normochromic red cells = 1 mg elemental iron; Calculate total volume of dose (iron dextran 50 mg/mL elemental iron); if total replacement dose is large, may consider dividing total dose and utilizing smaller incremental dosages not to exceed recommended maximum daily dosages for route.
Replacement iron (mg) = Blood loss (mL) x hematocrit (expressed as a decimal fraction)
Maximum daily dosage:
IV (Dexferrum, INFeD): 100 mg (2 mL)
Infants <5 kg: 25 mg (0.5 mL)
Children 5 to 10 kg: 50 mg (1 mL)
Children >10 kg and Adolescents: 100 mg (2 mL)
Anemia of chronic renal failure: IV: Note: Initiation of iron therapy, determination of dose, and duration of therapy should be guided by results of iron status tests combined with the Hb level and the dose of the erythropoietin stimulating agent. See Reference Range for target levels. There is insufficient evidence to recommend IV iron if ferritin level >500 ng/mL (KDOQI 2006).
Dosing based on the 2000 KDOQI Anemia Guidelines (KDOQI 2001). More recent KDOQI guidelines and the KDIGO guidelines no longer provide specific dosing recommendations or preferred product for intravenous iron supplementation (KDOQI 2006; KDIGO 2012).
Predialysis or peritoneal dialysis: Infants and Children: As a single dose repeated as often as clinically indicated:
<10 kg: 125 mg
10 to 20 kg: 250 mg
>20 kg: 500 mg
Hemodialysis: Infants, Children, and Adolescents: Administer during each dialysis for 10 doses total:
<10 kg: 25 mg
10 to 20 kg: 50 mg
>20 kg: 100 mg
Solutions for infusion should be diluted in 250 to 1,000 mL NS.
Total dose infusion (off-label dose): Dilute in 500 mL NS (Auerbach 2004)
Note: A test dose should be administered on the first day of therapy; administer slowly over at least 30 seconds and observe for at least 1 hour for hypersensitivity reaction, then administer the remainder of the day's therapeutic dose (dose minus test dose). Resuscitation equipment, medication, and trained personnel should be available. An uneventful test dose does not ensure an anaphylactic-type reaction will not occur during administration of the therapeutic dose.
IM (INFeD, DexIron [Canadian product]): Use Z-track technique (displacement of the skin laterally prior to injection); injection should be deep into the upper outer quadrant of buttock; alternate buttocks with subsequent injections. Administer test dose at same recommended site using the same technique.
IV: Test dose should be administered gradually over at least 30 seconds (INFeD) or 5 minutes (DexIron [Canadian product]), or over 1 to 2 minutes (INFeD) for cancer-/chemotherapy-associated anemia (Auerbach 2004). Subsequent dose(s) may be administered undiluted at a slow gradual rate not to exceed 50 mg/minute (maximum: 100 mg).
Avoid dilutions with dextrose (increased incidence of local pain and phlebitis).
Total dose infusion (in patients with cancer-/chemotherapy-associated anemia) (off-label administration): 1 hour after the test dose, administer the balance of the dose diluted in 500 mL NS and infuse at 175 mL/hour (Auerbach 2004)
Total dose infusion (in patients with CKD and iron deficiency anemia) (off-label administration): After initial test dose, administer total dose over 4 to 6 hours (Dossabhoy 2014). However, total dose infusions have been associated with an increased incidence of adverse effects 24 to 48 hours after the infusion.
Store at 20°C to 25°C (68°F to 77°F).
Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions. Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose. Consider therapy modification
Dimercaprol: May enhance the nephrotoxic effect of Iron Salts. Avoid combination
May cause falsely elevated values of serum bilirubin and falsely decreased values of serum calcium. Residual iron dextran may remain in reticuloendothelial cells; may affect accuracy of examination of bone marrow iron stores. Bone scans with 99m Tc-labeled bone seeking agents may show reduced bony uptake, marked renal activity, and excess blood pooling and soft tissue accumulation following IV iron dextran infusion or with high serum ferritin levels. Following IM iron dextran, bone scans with 99m Tc-diphosphonate may show dense activity in the buttocks.
Frequency not defined. Adverse event risk is reported to be higher with the high-molecular-weight iron dextran formulation.
Cardiovascular: Bradycardia, cardiac arrhythmia, chest pain, chest tightness, flushing, hypertension, hypotension, shock, syncope, tachycardia
Central nervous system: Chills, disorientation, dizziness, headache, loss of consciousness, malaise, paresthesia, seizure, unresponsive to stimuli
Dermatologic: Diaphoresis, pruritus, skin rash, urticaria
Gastrointestinal: Abdominal pain, diarrhea, dysgeusia, nausea, vomiting
Genitourinary: Hematuria, urine discoloration
Hematologic & oncologic: Leukocytosis, lymphadenopathy, purpura
Hypersensitivity: Anaphylaxis (includes acute respiratory distress, circulatory shock)
Infection: Sterile abscess
Local: Injection site reaction (includes injection site cellulitis, inflammation at injection site, injection site phlebitis, local soreness/soreness at injection site, pain at injection site, swelling at injection site), local discoloration (at the site of intramuscular injection)
Neuromuscular & skeletal: Amyotrophy (with intramuscular injection), arthralgia, arthritis, back pain, exacerbation of arthritis, myalgia, weakness
Respiratory: Bronchospasm, cyanosis, dyspnea, wheezing
Miscellaneous: Fever, fibrosis (with intramuscular injection)
<1%, postmarketing, and/or case reports: Angioedema, neoplasm (at former injection site)
ALERT: U.S. Boxed WarningAnaphylactic-type reactions:
Anaphylactic-type reactions, including fatalities, have followed the parenteral administration of iron dextran injection. Have resuscitation equipment and personnel trained in the detection and treatment of anaphylactic-type reactions readily available during iron dextran administration.
Administer a test dose of iron dextran prior to the first therapeutic dose. If no signs or symptoms of anaphylactic-type reactions follow the test dose, administer the full therapeutic iron dextran dose. During all iron dextran administrations, observe for signs or symptoms of anaphylactic-type reactions. Fatal reactions have followed the test dose of iron dextran injection. Fatal reactions have also occurred in situations in which the test dose was tolerated.
Patients with a history of drug allergy or multiple drug allergies may be at increased risk of anaphylactic-type reactions to iron dextran.Appropriate use:
Use iron dextran only in patients in whom clinical and laboratory investigations have established an iron-deficient state not amenable to oral iron therapy.
Concerns related to adverse effects:
• Hypersensitivity: [US Boxed Warning]: Anaphylactic-type reactions (including fatalities) are associated with parenteral administration of iron dextran. Administer only where resuscitation equipment and personnel trained in detection and treatment of hypersensitivity are available during administration. Administer a test dose prior to the first therapeutic dose. If no signs/symptoms of anaphylactic-type reactions follow the test dose, administer the full therapeutic dose. Monitor for signs/symptoms of hypersensitivity during infusion. Fatal reactions have occurred following a test dose and have occurred in patients who tolerated the test dose. Patients with a history of drug allergy or multiple drug allergies may be at increased risk of anaphylactic-type reactions. Concomitant use of ACE inhibitors may also increase the risk of hypersensitivity.
• Infusion reaction: Delayed (1 to 2 days) infusion reaction (including arthralgia, back pain, chills, dizziness, fever, headache, malaise, myalgia, nausea, and/or vomiting) may occur with large doses (eg, total dose infusion) of IV iron dextran; symptoms usually subside within 3 to 4 days.
• Allergies/asthma: Use with caution in patients with a significant history of allergies and/or asthma.
• Cardiovascular disease: Use with caution in patients with pre-existing cardiovascular disease; iron dextran may exacerbate cardiovascular complications.
• Hepatic impairment: Use with extreme caution in patients with serious hepatic impairment.
• Renal disease/impairment: In patients with chronic kidney disease (CKD) requiring iron supplementation, the IV route is preferred for hemodialysis patients; either oral iron or IV iron may be used for nondialysis and peritoneal dialysis CKD patients, although an initial 1- to 3-month trial of oral iron therapy is recommended (KDIGO 2012). Avoid use during acute kidney infection.
• Rheumatoid arthritis: Patients with rheumatoid arthritis may experience acute exacerbation of joint pain and swelling.
Concurrent drug therapy issues:
• Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Elderly: Anemia in the elderly is often caused by “anemia of chronic disease” or associated with inflammation rather than blood loss. Iron stores are usually normal or increased, with a serum ferritin >50 ng/mL and a decreased total iron binding capacity. IV administration of iron dextran is often preferred over IM in the elderly secondary to a decreased muscle mass and the need for daily injections.
• Pediatric: Intramuscular iron dextran use in neonates may be associated with an increased incidence of gram-negative sepsis.
• Appropriate use: [US Boxed Warning]: Use iron dextran only in patients where clinical and laboratory evidence has established the iron deficient state is not amenable to oral iron therapy. Discontinue oral iron prior to initiating parenteral iron therapy.
• Carcinogenicity: Cases of tumor development at prior intramuscular injection sites of iron-carbohydrate complexes have been reported.
• Iron overload: Exogenous hemosiderosis may result from excess iron stores; patients with refractory anemias and/or hemoglobinopathies may be prone to iron overload with unwarranted iron supplementation.
Monitor hemoglobin, hematocrit, reticulocyte count, serum ferritin, serum iron, TIBC; monitor for anaphylaxis/hypersensitivity reaction (during test dose, for 1 hour after test dose, and during and after therapeutic dose)
Cancer patients with anemia: Monitor iron, total iron-binding capacity, transferrin saturation, or ferritin levels at baseline and periodically (Rizzo 2010).
Chronic kidney disease: Monitor transferrin saturation more frequently following a course of IV iron (KDIGO 2012)
Iron dextran may cross the placenta.
Maternal iron requirements increase during pregnancy. Adequate iron concentrations to the fetus can be maintained regardless of maternal iron status, except in severe cases of anemia (IOM 2001). Untreated iron deficiency and iron deficiency anemia (IDA) in a pregnant female may be associated with adverse events, including low birth weight, preterm birth, or increased perinatal mortality (ACOG 95 2008; IOM 2001; Pavord 2012).
In general, treatment of iron deficiency or IDA in pregnancy is the same as in non-pregnant females. The majority of studies note iron therapy improves maternal hematologic parameters; however, information related to clinical outcomes in the mother and neonate is limited (Auerbach 2017a; Reveiz 2011; Siu 2015; Wong 2016). Oral preparations are generally sufficient; however, parenteral iron therapy may be used in females who cannot tolerate or will not take oral iron, in cases of severe iron deficiency, or when malabsorption is present (ACOG 95 2008; Pavord 2012). Due to limited safety data in early pregnancy, use of intravenous iron is generally not started until the second or third trimester (Breymann 2017a; Pavord 2012). Iron dextran has been evaluated for the treatment of IDA in pregnancy (Auerbach 2017a; Reveiz 2011; Wong 2016).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience injection site pain, skin discoloration, or irritation; diarrhea; abdominal pain; or change in taste. Have patient report immediately to prescriber severe headache, angina, severe dizziness, passing out, vision changes, severe loss of strength and energy, severe nausea, vomiting, burning or numbness feeling, blue/gray skin discoloration, swollen glands, hematuria, back pain, joint pain, chills, seizures, confusion, muscle pain, sweating a lot, shortness of breath, flushing, bradycardia, tachycardia, or abnormal heartbeat (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about iron dextran
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: iron products